206 related articles for article (PubMed ID: 25983003)
1. Metformin use improves the survival of diabetic combined small-cell lung cancer patients.
Kong F; Gao F; Liu H; Chen L; Zheng R; Yu J; Li X; Liu G; Jia Y
Tumour Biol; 2015 Sep; 36(10):8101-6. PubMed ID: 25983003
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Xu T; Liang G; Yang L; Zhang F
Clin Transl Oncol; 2015 Oct; 17(10):819-24. PubMed ID: 26063645
[TBL] [Abstract][Full Text] [Related]
3. Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus.
Lu H; Xie F; Huang Z; Qin J; Han N; Mao W
Adv Clin Exp Med; 2018 Sep; 27(9):1195-1199. PubMed ID: 30016011
[TBL] [Abstract][Full Text] [Related]
4. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
Xu T; Li D; He Y; Zhang F; Qiao M; Chen Y
World J Surg Oncol; 2018 Mar; 16(1):60. PubMed ID: 29558957
[TBL] [Abstract][Full Text] [Related]
6. Elevated RABEX-5 protein expression predicts poor prognosis in combined small cell lung cancer.
Zhang F; Zhang M; Hu G; Cai Q; Xu T
Tumour Biol; 2015 Nov; 36(11):8287-93. PubMed ID: 26002576
[TBL] [Abstract][Full Text] [Related]
7. Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.
Qiao M; Hu G
Tumour Biol; 2015 Sep; 36(10):7493-9. PubMed ID: 25910706
[TBL] [Abstract][Full Text] [Related]
8. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
Medairos RA; Clark J; Holoubek S; Kubasiak JC; Pithadia R; Hamid F; Chmielewski GW; Warren WH; Basu S; Borgia JA; Liptay MJ; Seder CW
J Thorac Cardiovasc Surg; 2016 Jul; 152(1):55-61.e1. PubMed ID: 27157918
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
12. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
[TBL] [Abstract][Full Text] [Related]
13. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
15. Metformin therapy associated with survival benefit in lung cancer patients with diabetes.
Wan G; Yu X; Chen P; Wang X; Pan D; Wang X; Li L; Cai X; Cao F
Oncotarget; 2016 Jun; 7(23):35437-45. PubMed ID: 27105507
[TBL] [Abstract][Full Text] [Related]
16. Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis.
Fan H; Bai S; Guan X; Ma W; Fu Y; Zhang X; Deng L; Tian J
Minerva Endocrinol (Torino); 2023 Jun; 48(2):214-221. PubMed ID: 33759443
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2009 Jan; 4(1):37-43. PubMed ID: 19096304
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with stage IV lung cancer with diabetes treated with metformin.
Lin JJ; Gallagher EJ; Sigel K; Mhango G; Galsky MD; Smith CB; LeRoith D; Wisnivesky JP
Am J Respir Crit Care Med; 2015 Feb; 191(4):448-54. PubMed ID: 25522257
[TBL] [Abstract][Full Text] [Related]
19. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
20. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
